Paper Details

  1. Home
  2. Paper Details

A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.

Author: AllendeM C, BellosoW H, BenetucciJ A, CahnP E, DaveyR T, EmeryS, LaneH C, LasalaM C, LawM G, LopardoG, LossoM H, NelsonE, SalomonH, SaraccoM

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Subcutaneous IL-2 at doses of 4.5 MIU and 7.5 MIU resulted in significant increases in CD4+ cell count in patients with HIV.
Paper Details　
Original Abstract of the Article :
A total of 73 patients with baseline CD4+ cell counts >/=350 cells/mm3 who were receiving combination antiretroviral therapy (ART) were randomized to receive subcutaneous interleukin-2 (IL-2; n=36) in addition to ART or to continue ART alone (n=37). Subcutaneous IL-2 was delivered at 1 of 3 doses (1...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1086/315430

データ提供：米国国立医学図書館（NLM）

Boosting Immune Function in HIV: Finding a New Oasis in the Desert of Antiretroviral Therapy

HIV infection can significantly impact the immune system, like a camel facing a harsh desert with limited resources. This research explores the potential of using subcutaneous interleukin-2 (IL-2) to enhance the immune response in HIV-infected patients receiving antiretroviral therapy (ART).

IL-2: A Potential Immune Booster for HIV Patients

The study found that subcutaneous IL-2, delivered at specific doses, resulted in significant increases in CD4+ cell count, a measure of immune function, compared to ART alone. This is like finding a hidden spring of water in the desert - a potential solution to boost the immune system and improve the health of HIV-infected individuals.

Hope for Improved Immune Function in HIV

This research offers a promising avenue for improving the immune response in HIV-infected patients. The findings suggest that IL-2 therapy could enhance immune function and potentially improve the long-term health and well-being of individuals living with HIV. This is a significant step forward in the fight against HIV, offering hope for a healthier future for those affected.

Dr.Camel's Conclusion

This study provides valuable insights into the potential of IL-2 therapy to enhance immune function in HIV-infected patients. The findings suggest that IL-2 could be a valuable tool in the fight against HIV, potentially improving the long-term health and well-being of individuals living with this challenging condition. This research is a beacon of hope in the desert of HIV treatment, offering a potential path towards a more robust immune system and a healthier future for PLWH.

Date :
  1. Date Completed 2000-07-20
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

10823761

DOI: Digital Object Identifier

10.1086/315430

Related Literature

Article Analysis
・Side Effects of zidovudine injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.